2012-11-23 10:18:27 -
Tinea Pedis (Athlete's Foot) - A US Market Report - a new market research report on companiesandmarkets.com
The US market for Tinea Pedis medications is projected to reach $555 million by 2015. Due to the dominance of generics, the market for tinea pedis treatment is currently sluggish. However, the market exhibits highly attractive commercial opportunity for novel drugs and formulation technologies under development that offer rapid penetration and are therapeutically more effective. Besides this, with the increase in aging population and diabetes patients, foot problems are also on rise, thereby generating a huge opportunity for foot care products manufacturers.
Skin conditions represent one of the most common health-related problems having a burdensome impact on the well-being of individuals. Although, majority of the skin diseases are not life threatening, yet several of such conditions hamper quality of life
and result in considerable healthcare expenses to the nation. About 70% of the population in the world is believed to experience a cutaneous mycotic infection at some point in their lives. Tinea pedis or athlete´s foot, the most prevalent mycotic infection worldwide, is caused by a dermatophyte in over 90% of the patients. This highly contagious disease results in itching, peeling, and scaling of the skin that can be generally treated at home using anti-fungal medications. In the US, Athlete´s foot is the second most common skin complaint, with about 45% of the people suffering periodically for 10 years or more. The problem is widespread with a high rate of recurrence and could lead to serious complications in individuals at risk. Over 70% of the population in the US suffer from tinea pedis at some time in their lives, while about 33% of such patients are estimated to contract toenail infections too. Besides age, diabetes also acts as a major risk factor, as diabetics are 50% more prone to a fungal infection as compared to non-diabetics.
With demanding and time consuming clinical trials thwarting the timely introduction of drugs, the prescription market for tinea pedis treatment is primarily dominated by generics, as stated by the new market research report on Tinea Pedis The anti fungal market has been less dynamic in recent years as no novel prescription anti-fungal agent has been launched since the past 5-6 years. Major pharmaceutical companies, in the absence of any patent protection, face stiff competition from generics, hence suffering decline in sales. Moreover as many of the existing over-the-counter medications are becoming less effective against various fungi strains, there exists wide opportunity for novel treatments. As most of the currently approved products for topical treatment of athlete´s foot have moderate efficacy and require long duration therapy extending to a month, current focus is towards development of more effective therapies that require half the treatment time. Players are also focusing on new formulation technologies that deliver the antifungal agent in large amounts and for a prolonged period into the skin, making one-shot treatment feasible.
The report titled Tinea Pedis (Athlete´s Foot): A US Market Report provides a comprehensive review of current market trends, key growth drivers, recent industry activity, research and development initiatives and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for the US market for the years 2006 through 2015. Key players profiled in the study include Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Kaken Pharmaceutical Co., Merck & Co. Inc., Nitric BioTherapeutics, Novartis AG, Sanofi-Aventis, Stiefel Laboratories, and Topica Pharmaceuticals.
Click for report details:
www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports
www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports
www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports
www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.
